A RESEARCH highlighted on Tuesday (26) that while the food and grocery industry has made great progress on diversity and inclusion, there is still more to do.
Although the vast majority (84 per cent) of companies in the food and grocery industry believe they are performing better today than they were five years ago on diversity and inclusion, fewer than half (45 per cent) of businesses have adopted a coordinated strategy on the topic, the study showed.
“And despite a genuine desire to do more across the industry, there is a reluctance to talk more openly about diversity and inclusion in case businesses are seen to be ‘behind the curve’,” the latest report on diversity and inclusion (D&I) in the food and grocery industry said.
The report was jointly launched by research and training charity IGD and executive search firm the MBS Group, in association with PwC.
It captured data from over 200 companies and conversations with over 100 chairs, chief executives and HR directors.
The study titled-‘Diversity in Food and Grocery’ aims to paint a true picture of diversity and inclusion in the industry, and to highlight some examples of how a number of organisations are driving greater diversity in practice.
The median gender pay gap within the food and grocery industry is lower than the UK economy as a whole (6.8 per cent versus 9.6 per cent), according to analysis by PwC.
However, fewer than 10 per cent of companies surveyed are prepared for ethnicity pay gap reporting, if it is introduced in the coming years.
On gender, an average of 27.6 per cent of board roles are occupied by women. At the executive committee level, this drops to 22.2 per cent, while 35.9 per cent of direct reports (into the executive committee) are women.
Compared with the latest Hampton-Alexander Review figures, food and grocery is ahead of the FTSE 350 cross-industry average at the executive committee and direct reports levels, although it is unlikely to reach the Hampton-Alexander target of 33 per cent women by the end of 2020.
At 11.4 per cent, the percentage of board members in the food and grocery industry from a black, Asian, and minority ethnic (BAME) background is very close to reflecting the UK working age population at large (12.5 per cent).
Some 5.7 per cent of executive committee members and 7.1 per cent of direct reports are BAME.
Most companies do not collect complete data around ethnic diversity.
When asked to consider their wider senior leadership teams, 27 per cent of interviewees were able to identify an openly LGTBQ leader within their business.
As most companies do not collect data on LGBTQ, it is difficult to measure how accurately the food and grocery industry workforce reflects wider society.
At the leadership level, across a sample of more than 50 companies, the average age of board members in food and grocery is 57 years.
This is slightly below the average across the FTSE 350 of 60 years old, while at 54, the average age of executive committee members is in line with the FTSE 350.
Jon Terry, People and Organisation Consulting Partner, PwC UK, said: “While the case for diversity and inclusion is strong in all business sectors, it’s especially so in an industry like food and grocery, where the customer reigns supreme.
“What’s clear from businesses that are making the strongest progress on diversity is that this requires the same board-level direction, organisation-wide push, understanding of the data and regular reporting, intervention and incentives that would be applied to any other strategic priority. In short, diversity and inclusion need to be a part of an organisation’s strategy and its cultural DNA.”
The study showed that 15 per cent of interviewees were able to identify someone with a physical disability, although no one was identified at the executive committee level, despite 19 per cent of the working-age population having a disability.
Again, most companies do not collect data on disability, but the approach to physical disability tends to be more reactive than proactive.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.